K-Ras ((G12D) の脱窒素性アルキレーションは,がん細胞における腫瘍性シグナル伝達を抑制する
PubMedで要約を見る
まとめ
この要約は機械生成です。研究者らは,臓がんの一般的な原因であるK-Ras (G12D) 変異を標的とした新しい化合物を開発しました. これらの薬は,健康な細胞や他のK-Ras変異に影響を与えることなく,選択的に癌細胞の成長を抑制します.
科学分野
- 腫瘍学
- 薬剤化学
- 分子生物学
背景
- 管腺がん (PDAC) は,主にKRAS変異によって引き起こされる非常に致死性の高い癌です.
- K-Ras ((G12D) はPDACで最も頻繁な腫瘍発生因子ですが,ターゲットを絞った治療法はありません.
- 現在の薬剤発見の取り組みは,K-Ras (G12D) を選択的に直接標的とした承認された治療法をもたらしていません.
研究 の 目的
- K-Ras (G12D) に対する新しい突然選択的阻害剤を開発する.
- 腫瘍性タンパク質に対する新しい共性標的戦略を探求する.
- KRAS ((G12D)) による癌細胞増殖を阻害する化合物を特定する.
主な方法
- α-ディアゾアセタミド化合物の合成と,共振抑制のためのスクリーニング.
- 変異部位にアスパルティック酸を標的にする脱窒素性アルキル化メカニズム
- KRAS ((G12D)) 変異体と野生型および他の変異性がん細胞系における化合物の有効性の評価
主要な成果
- 一連のα - ディアゾアセタミド化合物は,K-Ras ((G12D)) の選択的阻害を示した.
- 鉛化合物はK-Rasの下流のMAPK経路をアロステリックに抑制する.
- 同価結合メカニズムは,システインのような他の核愛体に比べてアスパルティック酸の選択性を示している.
- このアプローチは,野生型のK-RasとK-Ras (G12C) 変異を避けます.
結論
- 新しいα-ディアゾアセタミド化合物は,K-Ras ((G12D) を標的とする有望な戦略を提供します.
- 開発された共性メカニズムは,アスパルチン酸とグルタミン酸を含む標的アミノ酸の範囲を拡大します.
- この研究は,KRAS変異性がんに対する治療法の開発に新しい道を開きます.
関連する概念動画
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Guanine nucleotide exchange factors or GEF,
GTPase-activating proteins or GAPs, and
Guanine nucleotide-dissociation inhibitors or GDIs.
The GEF activates the GTPase by exchanging the bound-GDP with GTP. The...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

